This suggested that both CAR-T cells effectively suppressed the proliferative capacity of tumor cells (p < 0.05, p < 0.01), with the anti-HER2-13 CAR-T treatment group exhibiting a notably stronger effect (Fig. 7B,D). The gene discussed is ERBB2; the disease is neoplasm.